Fenwick & West represented Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, in its public offering of 5,750,000 shares of its common stock, including 750,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock, at a price to the public of $33.70 per share.
The offering was made pursuant to an effective shelf registration statement previously filed with the SEC.
Leerink Partners LLC, Evercore Group LLC and Guggenheim Securities, LLC acted as joint book-running managers for the offering. Needham & Company, LLC acted as co-manager.
The Fenwick transaction team included corporate partners Michael Brown (Picture) and Douglas Cogen, and associates Katherine Duncan, Brendan Franich, Jennifer Hitchcock, Bryce Daigle and Jeremy Kazzaz.
Involved fees earner: Michael Brown – Fenwick & West LLP; Douglas Cogen – Fenwick & West LLP; Katherine Duncan – Fenwick & West LLP; Brendan Franich – Fenwick & West LLP; Jennifer Hitchcock – Fenwick & West LLP; Bryce Daigle – Fenwick & West LLP; Jeremy Kazzaz – Fenwick & West LLP;
Law Firms: Fenwick & West LLP;
Clients: Dermira, Inc.;